Larry Goldstein to Secondary Prevention
This is a "connection" page, showing publications Larry Goldstein has written about Secondary Prevention.
Connection Strength
1.377
-
How much can be gained by more systematic prevention of stroke? Int J Stroke. 2008 Nov; 3(4):266-71.
Score: 0.316
-
Advances in Stroke: Treatments-Preventive. Stroke. 2022 02; 53(2):608-610.
Score: 0.197
-
Chronic kidney disease and stroke. Adv Chronic Kidney Dis. 2014 Nov; 21(6):500-8.
Score: 0.119
-
Advances in stroke: Prevention and health services delivery 2012-2013. Stroke. 2014 Feb; 45(2):371-2.
Score: 0.113
-
Regional variation in recommended treatments for ischemic stroke and TIA: Get with the Guidelines--Stroke 2003-2010. Stroke. 2012 Jul; 43(7):1858-64.
Score: 0.101
-
Secondary preventive medication persistence and adherence 1 year after stroke. Neurology. 2011 Sep 20; 77(12):1182-90.
Score: 0.096
-
Posttransplantation hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy. Am J Transplant. 2011 Mar; 11(3):511-7.
Score: 0.092
-
Similar secondary stroke prevention and medication persistence rates among rural and urban patients. J Rural Health. 2011; 27(4):401-8.
Score: 0.092
-
Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology. 2008 Jun 10; 70(24 Pt 2):2364-70.
Score: 0.074
-
Death and rehospitalization after transient ischemic attack or acute ischemic stroke: one-year outcomes from the adherence evaluation of acute ischemic stroke-longitudinal registry. J Stroke Cerebrovasc Dis. 2013 Oct; 22(7):e181-8.
Score: 0.026
-
Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial. Stroke. 2009 Jul; 40(7):2486-92.
Score: 0.021
-
The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) registry: design, rationale, and baseline patient characteristics. Am Heart J. 2009 Mar; 157(3):428-435.e2.
Score: 0.020
-
Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis. 2009 Jun; 204(2):515-20.
Score: 0.020
-
Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008 May; 39(5):1647-52.
Score: 0.019
-
High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006 08 10; 355(6):549-59.
Score: 0.017
-
Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation. 2006 Mar 14; 113(10):e409-49.
Score: 0.016
-
Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Cerebrovasc Dis. 2003; 16(4):389-95.
Score: 0.013
-
Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Stroke. 2002 Jul; 33(7):1934-42.
Score: 0.013
-
An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl. 2000 Nov; 6(6):741-8.
Score: 0.011